Keywords ferric carboxymaltose, intravenous iron, iron deficiency anaemia, iron sucrose, paediatric
Introduction
Anaemia is one of the most common extraintestinal complications of inflammatory bowel disease (IBD). It is more common in children than adults [1] , affecting an estimated 70% of children with IBD [2] , and occurs more frequently in Crohn's disease (CD) than ulcerative colitis [3] . Anaemia in IBD is multifactorial and closely associated with IBD activity. The leading cause is iron deficiency anaemia (IDA) followed by anaemia of chronic disease. ID results from gastrointestinal blood loss, poor dietary intake and reduced iron bioavailability. Iron malabsorption is a contributing factor especially in CD affecting the small bowel [4] . Nearly 90% of children with IBD have ID with or without associated anaemia [1] . It is increasingly recognized that IDA is a significant contributor to morbidity in IBD.
Chronic IDA in children causes fatigue, impairs cognitive development and is associated with lower intelligence quotients, attention deficit and other behavioural disorders [5] . Immune regulation and growth are also negatively impacted [6] . These effects are apparent in ID even in the absence of anaemia. Adult IBD patients who are anaemic report low quality of life indices and there is a marked improvement in this when haemoglobin (Hb) is corrected in adults with IBD [7] . For these reasons, early recognition and prompt and effective treatment of ID(A) are of paramount importance in IBD care.
Oral iron supplementation may be considered first line therapy, although issues with tolerance and adherence to prolonged treatment courses often impair therapeutic success. Blood transfusion as a therapy for IDA carries costs and risks, which are well recognized. Newer intravenous (IV) iron preparations with a more favourable side effect profile have become available in the last decade including iron sucrose (IS) and ferric carboxymaltose (FCM), which have been shown to be safe and effective in adults [8] [9] [10] . Only a small number of studies on the safety and efficacy of modern IV iron products have been conducted in children. Most of these studied IS not FCM and concerned small numbers of children with chronic kidney disease [11] [12] [13] [14] . More recently investigators have shown encouraging safety and efficacy of IS in 24 children with IBD and IDA [15] .
Here we describe our 38-month experience of FCM and IS in children with IBD with a focus on safety and efficacy.
Methods
All children with IBD who received IV iron in a single regional referral centre between April 2013 and May 2016 were retrospectively identified via pharmacy records. Inclusion criteria were therefore IBD and IDA. In most cases, oral iron was used as first-line treatment for IDA. IV iron was used in the following circumstances: (i) patient reported side effects with oral iron; (ii) non-resolution of IDA with 3 months of oral iron; (iii) physician assessment of severity of either IBD or IDA contraindicates trial of oral iron. Anaemia was defined as Hb below reference range for age and sex according to the World Health Organization [16] . ID was diagnosed by the combination of low serum iron, low mean red cellular volume, high transferrin and low iron saturation. Ferritin falls in ID, but rises in the acute phase [17] , complicating its interpretation as a marker for IDA in IBD. Ferritin was therefore defined as low in the context of C-reactive protein (CRP; ferritin <30 if CRP <10 and ferritin <100 if CRP >10). Children with severe atopy or allergies or history of prior anaphylaxis were excluded from the study, and were not offered IV iron therapy.
Choice of iron preparation was based primarily on patient age, with those aged under 12 years receiving IS and those over 12 years receiving FCM. Demographic data, disease status, iron preparation type, dose and number of infusions were recorded. Dosage was calculated as a function of body weight and Hb, as per manufacturers' recommended dosing schedules. Iron preparations were infused according to British National Formulary guidelines. FCM infusions were administered over 15-30 min, and IS over 50-70 min. All patients completed a 2-h inpatient observation period postinfusion, during which vital signs were recorded at regular intervals.
Adverse reactions were identified by detailed review of written case notes, nursing observations, and nursing, pharmacy and medical electronic records. Efficacy was assessed by pre-and post-treatment iron, transferrin saturation, ferritin, transferrin and Hb levels. Changes in CRP and erythrocyte sedimentation rate (ESR) were also recorded.
The study was approved and registered as a Clinical Audit by the Local Quality Governance Department.
Results
Forty-one children with IBD received 48 infusion episodes (104 IV iron infusions) over the study period. 23 children were female and 18 male. Mean age was 13.5 years, ranging from 3 to 17 years. Eighteen had CD (44%) and 23 ulcerative colitis (56%). Thirty-five patients received 58 FCM infusions. Five of these 35 went on to require a second FCM infusion episode at a later date during the study period, resulting in 40 FCM infusion episodes in total. Thus, FCM was given at an average of 1.5 infusions per patient episode. Seven patients received 46 IS infusions; one of these required a further IS infusion episode during the study period. Thus, IS was given at an average of 5.8 infusions per patient episode. One patient initially completed a course of IS infusions and 11 months later received FCM as she moved age group. The doses ranged from 500 to 1000 mg per infusion for FCM and 70 to 100 mg per infusion for IS. Where an individual received a second infusion episode, the median time between episodes was 12.5 months (range 7-21).
All (Table 2) . Thus, there is no suggestion from the current study that efficacy of iron infusion is affected by disease severity.
Discussion
Published evidence strongly supports both proactive treatment of IDA in IBD, and the use of newer IV iron preparations, which are efficacious with fewer doses and less allergenic than their predecessors. As in many other areas of paediatric practice, treatment of children has relied upon the extrapolation of adult research. Here we contribute safety and efficacy data for IV iron therapy in paediatric IBD.
Oral ferrous supplements are oxidized in the gut, produce activated hydroxyl radicals that affect the mucosa [18] and may provoke gastrointestinal symptoms including bloating, nausea and pain, which can be exacerbated in patients with IBD [19] . In inflammatory diseases, iron absorption is reduced and increased hepcidin, an acute phase protein, plays a key role. In health, hepcidin levels rise with total body iron stores and protect against iron overload. Hepcidin is upregulated in systemic inflammatory states by interleukins-6 Table 1 Haematinic indices pre-and post-treatment. Data were imported into STATA version 14. Descriptive statistics: mean, standard deviation (SD), minimum and maximum were calculated for pre-and post-treatment values of haemoglobin (Hb), transferrin saturation, CRP, ESR, transferrin, ferritin and iron. Paired sample Student t tests for paired differences were calculated for pre-and post-treatment values for each variable. Hb, transferrin, transferrin saturation, Fe and ESR: P < 0.0001. Ferritin: P < 0.0002. CRP: P = 0.94 and -1, and impairs absorption of oral iron via multiple mechanisms [20] . Adherence to oral iron therapy, particularly in adolescent IBD patients, is frequently suboptimal [21] . Even in the adherent patient, several months of oral supplementation may be required to achieve target Hb. The first IV iron introduced in the 1930s, an iron oxyhydroxide complex [22] , had major side effects and was only indicated in rare circumstances [23] . In the 1950s, a high-molecular weight iron dextran was developed in which the iron oxyhydroxide complex was surrounded by a shell of dextran polymers [24] . This improved its bioavailability and side effect profile; however, allergic reactions were frequent [25] . Gradually, low-molecular weight iron dextran compounds became available, which caused fewer adverse reactions [26] . Later, ferric gluconate was introduced and was safer than iron dextran [27] .
In 2000, IS came into clinical use; its incidence of anaphylaxis was lower at 0.002%, compared to 0.04% with ferric (G) C-reactive protein (CRP; mg ml -1 ) P = 0.94 pre-and post-treatment Table 2 Hameoglobin ( gluconate and 0.6-2.3% with high-molecular weight iron dextran [28] . The biggest drawback of IS is its low maximum single administrable dose, resulting in multiple separate infusions to reach therapeutic dose. Finally, in 2007 FCM became available with a license in Europe for patients older than 14 years. A single dose of 1000 mg of iron can be given, and administered relatively rapidly, over 15-60 min [29] , with no requirement for test dose, thus reducing hospital attendance times and costs.
Of the 40 children in our series who received 104 infusions of IV iron none experienced major or lasting adverse event. In our series, FCM was associated with a 5.7% mild reaction rate (rash) and IS with a 14% mild reaction rate (itch and eye swelling). These numbers do not allow comparative conclusions to be drawn between the two iron preparations in terms of safety; however, we provide evidence that parenteral iron and in particular FCM is safe and well tolerated in children.
We show that IV iron is a highly efficacious treatment for IDA in children with IBD, inducing clinically and statistically significant increments in Hb, Fe and transferrin saturation, and reductions in transferrin and ESR. The reduction in ESR was not paralleled by significant reduction in CRP and reflects resolution of IDA rather than change in IBD activity.
As well as its lower reported incidence of anaphylaxis, FCM offers a less onerous dosing schedule, no requirement for test dose and shorter infusion time in contrast to IS. In our series we demonstrate safety of FCM in children at least as young as 12 years. This is an off-label use of this medication (age <14 years). The British Society of Paediatric Gastroenterology Hepatology and Nutrition (BSPGHAN) has published iron therapy guidelines in which it is simply noted that parenteral iron preparations are not licenced in children aged <14 years [30] . Other investigators have more recently demonstrated safety of FCM in even younger age groups, not specific to IBD [31] .
We have selected lower risk cases by excluding those with a personal history of severe allergy, atopy or anaphylaxis to other agents. Whilst the safety profile of parenteral iron in children is probably comparable to that in adults, oral iron remains a safer and less costly option, and should be trialled in the first instance in most cases, where IDA is mild to moderate, IBD activity is quiescent and there is no history of intolerance.
We acknowledge the limitations of this study associated with its retrospective design and heterogeneous clinical nature. Whilst prospective randomized trial design is needed in the field, the current study provides supporting evidence for the safety and efficacy of new-generation IV iron preparations in the treatment of IBD-associated IDA in children.
